Global Cyclin-Dependent Kinase Inhibitor Drug Pipeline Research Report 2023: Therapeutics Assessment by Product Type, Stage, Route of Administration, and Molecule Type
20 nov. 2023 10h28 HE
|
Research and Markets
Dublin, Nov. 20, 2023 (GLOBE NEWSWIRE) -- The "Cyclin-Dependent Kinase Inhibitor - Pipeline Insight, 2023" drug pipelines has been added to ResearchAndMarkets.com's offering."Cyclin-Dependent...
Global Antibody Drug Conjugate (ADC) Competitive Landscape Report 2023: Company Analysis, Therapeutic Assessment, Pipeline Assessment, Inactive Drugs Assessment, Unmet Needs
17 nov. 2023 08h13 HE
|
Research and Markets
Dublin, Nov. 17, 2023 (GLOBE NEWSWIRE) -- The "Antibody Drug Conjugate - Competitive landscape, 2023" report has been added to ResearchAndMarkets.com's offering. This report provides...
Provectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy PV-10 for Advanced Cutaneous Melanoma
15 nov. 2023 09h00 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today provided updated data from an ongoing Phase 1b/2 clinical trial of investigational cancer immunotherapy PV-10 (rose...
Exploring CAR-T Therapy: A New Era in Cancer Treatment
14 nov. 2023 04h48 HE
|
Research and Markets
Dublin, Nov. 14, 2023 (GLOBE NEWSWIRE) -- The "CAR-T Therapy- Pipeline Insight, 2023" drug pipelines has been added to ResearchAndMarkets.com's offering. The research report delves into several...
Pharmacokinetics Services Market Report 2023: A Global $1.75+ Billion Industry by 2030 - Analysis by Drug Type (Small Molecules) & End-use (Biotechnology & Pharmaceutical Companies)
14 nov. 2023 03h13 HE
|
Research and Markets
Dublin, Nov. 14, 2023 (GLOBE NEWSWIRE) -- The "Pharmacokinetics Services Market Size, Share & Trends Analysis Report By Drug Type (Small Molecules), By Application (SMEs) By End-use...
Provectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy PV-10 for Metastatic Uveal Melanoma
13 nov. 2023 08h00 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today provided updated data from an ongoing Phase 1 clinical trial of investigational cancer immunotherapy PV-10 (rose bengal...
Global Active Pharmaceutical Ingredient CDMO Market to Reach $156.3 Billion by 2030, Driven by Rising R&D Investments and Demand for Generic Drugs
10 nov. 2023 08h03 HE
|
Research and Markets
Dublin, Nov. 10, 2023 (GLOBE NEWSWIRE) -- The "Active Pharmaceutical Ingredient CDMO Market Size, Share & Trends Analysis Report By Product (Highly Potent API, Antibody Drug Conjugate), By...
invIOs and Dana-Farber Cancer Institute start collaboration to study novel small molecule INV501 for treatment of glioblastoma
09 nov. 2023 05h30 HE
|
invIOs GmbH
Preclinical study will be conducted by Dr. David Reardon’s research groupImmune-activating small molecule INV501 will be tested as treatment for aggressive brain cancer VIENNA, Austria and BOSTON,...
Provectus Biopharmaceuticals Announces Presentation of Preclinical PV-10 Vaccine Adjuvant Data at Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
06 nov. 2023 08h00 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that preclinical data from ongoing research on the potential use of investigational cancer immunotherapy...
Societal CDMO to Report Financial Results for Third Quarter 2023 on November 8, 2023
01 nov. 2023 16h05 HE
|
Societal CDMO, Inc.
SAN DIEGO and GAINESVILLE, Ga., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO” or “Societal”; NASD: SCTL), a contract development and manufacturing organization (CDMO)...